Denosumab Xgeva Not Approved For Metastasis Prevention
Amgen's application for expanded indications for denosumab ( Xgeva ) were turned down by the FDA (Food and Drug Administration) - the expanded indications were to include bone metastases prevention in patients with castration-resistant prostate cancer. The FDA told Amgen in a CRL (Complete Response Letter) that evidence regarding better bone metastasis-free survival was "insufficient", and as such, the potential adverse effects of osteonecrosis of the jaw, among others were not so far compellingly outweighed by the benefits.
Personalizing Prostate Cancer Treatment
Each year in the UK alone, about 37, 000 men are diagnosed with prostate cancer. Given that prostate cancers can be genetically quite different, means they affect the way in which they react to treatments. The Prostate Cancer Foundation and the American Association for Cancer Research have just announced a prostate cancer "Dream Team", in which Professor Johann de Bono from The Royal Marsden and The Institute of Cancer Research (ICR) will be collaborating with other expert prostate cancer researchers in a $10 million global effort to drive the development of personalized treatment for this disease.
Aggressive Prostate Cancer Risk Linked With Two Genetic Deletions In Human Genome
According to a study published online in Proceedings of the National Academy of Sciences (PNAS), researchers have identified two inherited-genetic deletions in the human genome associated to the development of prostate cancer. The study, led by Weill Cornell Medical College researchers in collaboration with the Brigham and Women's Hospital and Innsbruck University Hospital, reveals that men are three or four times more likely to develop the disease depending on the genetic variant they inherit.